tbuckley/cabot-search huggingface dataset:
Alpha-1 antitrypsin deficiency–associated panniculitis
Authors: Alessandro N. Franciosi, James Ralph, Naoimh J. O'Farrell, Colm Buckley, Christian Gulmann, Marina O'Kane, Tomás P. Carroll, Noel G. McElvaney
Journal: Journal of the American Academy of Dermatology (2021)

Panniculitis represents a rare and potentially lethal manifestation of alpha-1 antitrypsin deficiency (AATD). Evidence regarding management is limited to case reports and small case series. We sought to clarify typical features and investigation of AATD-associated panniculitis and assess the evidence regarding therapeutic options.Articles and abstracts published between 1970 and 2020 were identified by searches of MEDLINE, PubMed, and secondary searches of references from relevant articles using the search terms "panniculitis," "alpha-1," "antitrypsin," "deficiency," and "Weber-Christian."We identified 117 cases of AATD-associated panniculitis. In 1 series, AATD was present in 15% of all cases of biopsy-proven panniculitis. Failure to achieve clinical response was seen in all instances of systemic steroid use. Dapsone, although effective and accessible, is frequently associated with failure to achieve remission. In these instances, intravenous AAT augmentation therapy generally resulted in response.AATD may be more prevalent among patients presenting with panniculitis than previously thought. Patients presenting with panniculitis and systemic illness show high mortality risk. Although most cases are associated with the severe ZZ-genotype, moderate genotypes may also predispose to panniculitis. Dapsone remains the most cost-effective therapeutic option, whereas intravenous AAT augmentation remains the most efficacious. Finally, glucocorticoids appear ineffective in this setting.
再狭窄の再内皮化治療:一酸化窒素再生(NO)を伴うバルーン障害後の新生内膜形成抑制を招くヒト肝細胞成長因子(HGF)遺伝子のin vivo遺伝子導入
Authors: Nakamura S, Moriguchi A, Morishita R, Higaki J, Kaneda Y, Nakamura T, Ogihara T
Journal: Circulation (1997)
Z-Disc Genes in Hypertrophic Cardiomyopathy: Stretching the Cardiomyopathies?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: J. Martijn Bos, Michael J. Ackerman
Journal: Journal of the American College of Cardiology (2010)
OP0078 Assessment of a biofeedback program to treat chronic low back pain
Authors: J Natour, KF Sousa, AG Orfale, JR Leite
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Low back pain is a common problem that can affect up to 80% of adults during their lives. The symptoms of these chronic pain patients include affective, cognitive and behavioural components. Many interventions have been found to be beneficial in the rehabilitation of chronic low back pain patients, one of them is biofeedback. <h3>Objectives</h3> Assess the efficacy of a biofeedback program for chronic low back pain patients and its impact in their pain, disabilities, and depression and anxiety symptoms; and promove higher abdominal muscles contraction levels without increasing paraspinal muscles contraction levels. <h3>Methods</h3> Sixty patients with chronic low back pain were randomly assigned into a control and a treatment group and were oriented to take analgesics when necessary. The treatment group participated in a biofeedback program (8 weeks) that included: global relaxation trainning and abdominal strength exercises with and without biofeedback and cognitive reestructuring techniques. The outcome measures used were Visual Analogue Scale (VAS), Roland-Morris questionnaire, Schöber Index, Beck Depression Inventory (BDI) and State-trait Anxiety Inventory (STAI) in the beginning and at the end of the observation period. Contraction (EMG) levels of abdominals and paraspinal muscles were registered in the beginning, after 1 month and at the end of the observation period. <h3>Results</h3> At the end of the observation period treatment group patients improved significantly on VAS (p = 0,012) and STAI (p = 0,003). Roland-Morris questionnaire improved in both groups without differences between them (treatment p = 0,0001 and control p = 0,006). The control group improved significantly on BDI (p = 0,013). There were no differences in the contraction levels of abdominals and paraspinals muscles, and neither in the Shöber Index. <h3>Conclusion</h3> Our biofeedback program reduced pain and anxiety symptoms of chronic low back pain patients. The disabilities improved in both groups. The program didn't change depression symptoms and the paraspinal contraction levels while contracting abdominal muscles <h3>References</h3> Flor H, Haag G, Turk DC, Koehler H. Efficacy of EMG biofeedback, pseudotherapy, and conventional medical treatment for chronic rheumatic back pain. Pain 1983;17: 21–31 Helewa A, Goldsmith CH, Lee P, Smythe HA, Forwell L. Does strengthening the abdominal muscles prevente low back pain – A randomized controlled trial. J Rheumatol. 1999;26(8):1808–15 Malone MD, Strube MJ. Meta-analysis of non-medical treatment for chronic pain – Review article. Pain 1988;34:231–44 Newton-John TR, Spence SH, Schotte D. Cognitive-behavioural therapy versus emg biofeedback in the treatment of chronic low back pain. Behav Res Ther. 1995;33:691–7 Turner JA, Jensen MP. Efficacy of cognitive therapy for chronic low back pain. Pain 1993;52:169–77
Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)
Authors: Issa F. Khouri, Hui Gao, Denái R. Milton, Martin Korbling, Celina Ledesma, Luis E. Fayad, Elias J. Jabbour, Alison M. Gulbis, James M. Reuben
Journal: Blood (2017)
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Authors: Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B Olawaiye, Susan L Ellard, Johanne I Weberpals, Andrea E Wahner Hendrickson, Gini F Fleming, Stephen Welch, Neesha C Dhani, Tracy Stockley, Prisni Rath, Katherine Karakasis, Gemma N Jones, Suzanne Jenkins, Jaime Rodriguez-Canales, Michael Tracy, Qian Tan, Valerie Bowering, Smitha Udagani, Lisa Wang, Charles A Kunos, Eric Chen, Trevor J Pugh, Amit M Oza
Journal: The Lancet (2021)
Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception
Authors: David K. Turok, Alexandra Gero, Rebecca G. Simmons, Jennifer E. Kaiser, Gregory J. Stoddard, Corinne D. Sexsmith, Lori M. Gawron, Jessica N. Sanders
Journal: New England Journal of Medicine (2021)

In the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contraception. Currently, clinicians offer only copper IUDs for emergency contraception because data are lacking on the efficacy of the levonorgestrel IUD for this purpose.This randomized noninferiority trial, in which participants were unaware of the group assignments, was conducted at six clinics in Utah and included women who sought emergency contraception after at least one episode of unprotected intercourse within 5 days before presentation and agreed to placement of an IUD. We randomly assigned participants in a 1:1 ratio to receive a levonorgestrel 52-mg IUD or a copper T380A IUD. The primary outcome was a positive urine pregnancy test 1 month after IUD insertion. When a 1-month urine pregnancy test was unavailable, we used survey and health record data to determine pregnancy status. The prespecified noninferiority margin was 2.5 percentage points.Among the 355 participants randomly assigned to receive levonorgestrel IUDs and 356 assigned to receive copper IUDs, 317 and 321, respectively, received the interventions and provided 1-month outcome data. Of these, 290 in the levonorgestrel group and 300 in the copper IUD group had a 1-month urine pregnancy test. In the modified intention-to-treat and per-protocol analyses, pregnancy rates were 1 in 317 (0.3%; 95% confidence interval [CI], 0.01 to 1.7) in the levonorgestrel group and 0 in 321 (0%; 95% CI, 0 to 1.1) in the copper IUD group; the between-group absolute difference in both analyses was 0.3 percentage points (95% CI, -0.9 to 1.8), consistent with the noninferiority of the levonorgestrel IUD to the copper IUD. Adverse events resulting in participants seeking medical care in the first month after IUD placement occurred in 5.2% of participants in the levonorgestrel IUD group and 4.9% of those in the copper IUD group.The levonorgestrel IUD was noninferior to the copper IUD for emergency contraception. (Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; ClinicalTrials.gov number, NCT02175030.).
FRI0135 Predictive value of the induced sputum cytology in patients with pulmonary involvement in systemic connective tissue diseases
Authors: P Bradna, Z Parakova, B Kral, Z Hrncir, Z Dvorak, T Soukup
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Pulmonary involvement is frequent and serious organ manifestation of connective tissue diseases. Diagnosis needs to use the set of examination procedures. Some of these methods represent stress for patient, others are expensive for repetitive use. Method of induced sputum is simple, non-invasive, reproducible method, measuring intensity of inflammatory reaction in bronchial asthma and interstitial lung disease patients. We have found increased frequency of pulmonary involvement in patients with leucocyte predominance in induced sputum. <h3>Objectives</h3> Aim of current study was to estimate predictive value of cytology of induced sputum for progressive pulmonary involvement in patients with connective tissue diseases. <h3>Methods</h3> Forty-five patients with established diagnosis of connective tissue disease (SLE, PSS, PM/DM), were examined for pulmonary involvement (X-ray, spirometry, diffusion lung capacity, high resolution CT scan, event.bronchoscopy with BAL). Induced sputum was obtained after inhalation of 5 ml of 3 percent solution of natrium chloride by ultrasonographic nebuliser. The induced sputum was cultivated, cytological and immunophenotypisation examinations were made. Pulmonary function tests and induced sputum examinations were repeatedly done after 9–12 moths. <h3>Results</h3> We have detected progression of pulmonary involvement in 16 patients Cytological features of leucocyte predominance were found in 12 of them. In 29 non-progressive patients was leucocyte predominance found in only six cases. Respiratory infection was excluded. <h3>Conclusion</h3> Method of induced sputum seems, after thoroughgoing appreciation, to be the interesting possibility of simple, non-invasive method for screening of pulmonary involvement progression in patients, suffering by connective tissue diseases. <h3>References</h3> Olivieri D, DIppolito R, Chetta A. Induced sputum: diagnostic value in interstitial lung disease. Curr Opin Pulm Med. 2000;6(5):411–14 Bradna P, Parakova Z, Kral B, Hrncir Z, <i>et al</i>. Method of induced sputum in screening of pulmonary involvement in connective tissue diseases. Rheumatologia 2000;14(2):91
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Authors: Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman
Journal: The Lancet (2021)
A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
Authors: Hiroki Hara, Takuro Mizukami, Keiko Minashi, Tomohiro Nishina, Naoki Takahashi, Yusuke Amanuma, Akio Nakasha, Masaki Takahashi, Takako Eguchi Nakajima
Journal: Journal of Clinical Oncology (2021)

210 Background: Trifluridine/tipiracil (FTD/TPI) or irinotecan is a treatment option in the heavily pretreated patients with advanced gastric cancer (AGC) with the limited efficacy. Thus, we investigated the recommended dose of trifluridine/tipiracil (FTD/TPI) and irinotecan for these patients. Methods: Patients who refractory to fluoropyrimidine, platinum and taxane were enrolled into four cohorts (Level 1A/1B/2A/2B) used a escalated dose of irinotecan [100 (Level 1) or 125 mg/m 2 (Level 2) on Days 1 and 15 of a 28-day schedule] with 2 dosage schedules of FTD/TPI:35 mg/m 2 /dose, twice daily (bid), on days 1-5 and 8-12 of a 28-day cycle (Level A) or on days 1-5 and days 15-19 of a 28-day cycle (Level B). The primary objectives were the determination of the maximum tolerated dose, dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D) for phase I part and the evaluation of disease control rate (DCR) targeting &gt; 55% in all enrolled patients for phase II part. Results: Eleven patients were enrolled from 4 institutions in Japan; 2 at Level 1A, 3 at Level 1B and 6 at Level 2B. DLTs occurred in 2/2 patient at Level 1A (Grade 3 gum infection and Grade 3 febrile neutropenia on Day 29, outside the 28-day DLT assessment period, determined equivalent to DLT), and 2/6 patients at Level 2B (Grade 3 mucositis oral and Grade 3 febrile neutropenia). Grade 3 or higher treatment-related adverse events were neutropenia (90.9%), leukopenia (54.5%), anemia (45.5%) and febrile neutropenia (18.2%). One patient at Level 2B achieved partial response and the DCR was 72.7% (95% CI 39.0- 94.0%). The median progression-free survival and overall survival was 3.0 months (95% CI 0.92- not reached) and 10.2 months (95% CI 2.2- not reached), respectively. Conclusions: The RP2D was determined to be Level 1B although further investigation to explore optimal regimen is needed. Clinical trial information: UMIN000031346.
Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.
Authors: Daryl Chia, Raghav Sundar, Guo Wei Kim, Jiajun Ang, Jeffrey Lum, Min En Nga, Chee Cheng Ean, Hon Lyn Tan, Jingshan Ho, Natalie Ngoi, Matilda Lee, Vaishnavi Muthu, Gloria Chan, Angela Pang, Yvonne Ang, Joan Choo, Joline Si Jing Lim, Asim Shabbir, Wei-Peng Yong, Jimmy Bok Yan So
Journal: Journal of Clinical Oncology (2021)

165 Background: The addition of intraperitoneal (IP) paclitaxel (PTX) to systemic chemotherapy comprising taxane/fluoropyrimidine doublet has shown promising results for patients with gastric cancer (GC) and peritoneal metastases (PM). However, this has not been studied in combination with platinum/fluoropyrimidine doublet which is the current standard-of-care for metastatic GC. We conducted a prospective phase 2 trial of IP PTX with capecitabine and oxaliplatin (XELOX) in patients with GCPM. Methods: The trial enrolled 44 patients with GCPM who received treatment comprising IP PTX (40mg/m 2 on day 1,8), PO capecitabine (1000mg/m 2 twice daily from day 1-14) and IV oxaliplatin (100mg/m 2 on day 1) in 21-day cycles. Patients with synchronous GCPM were eligible for conversion surgery comprising radical gastrectomy if they had good response after chemotherapy, negative cytology on 2 consecutive peritoneal fluid assessments, no extraperitoneal metastasis and no peritoneal disease during surgery. The primary endpoint was overall survival and secondary endpoints were progression-free survival and safety. Outcomes from the trial were also compared with a retrospective cohort of 39 patients with GCPM who received identical systemic chemotherapy (SC) comprising platinum/fluoropyrimidine agents alone. Results: The median OS for the IP and SC groups was 14.6 and 10.6 months (HR 0.44; 95% CI, 0.26-0.74; P=0.002). The 1-year OS was 67.8% in the IP group and 32.3% in the SC group (Logrank p&lt;0.001). The median PFS for the IP and SC group was 9.5 and 4.4 months respectively (HR 0.39; 95% CI, 0.25-0.66; P&lt;0.001). Patients in the SC group were younger (IP vs. SC, 61 vs. 56 years, p=0.021) and had better baseline performance status (ECOG 0, IP vs. SC, 47.7% vs. 76.9%, p=0.007) compared to the IP cohort. In the IP group, conversion surgery was performed in 36.1% (13/36) of patients, with a median OS of 24.2 (95%CI 13.1 – 35.3) months and 1-year OS of 84.6%. Wound-related complications requiring the port to be explanted or re-sited occurred in 9% (4/44) of patients. Conclusions: IP PTX with XELOX is a promising treatment option for GCPM patients. For patients with good response, conversion surgery was feasible with favourable outcomes. Clinical trial information: NCT01739894. [Table: see text]
Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres
Authors: Xin Song, Haifeng Ji, Yupei Li, Yuqin Xiong, Li Qiu, Rui Zhong, Meng Tian, Jayachandran N. Kizhakkedathu, Baihai Su, Qiang Wei, Weifeng Zhao, Changsheng Zhao
Journal: Nature Biomedical Engineering (2021)
Progression of Heart Failure From AHA/ACC Stage A to Stage B or Even C: Can We All Agree We Should Try to Prevent This From Happening?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Daniel J. Lenihan
Journal: Journal of the American College of Cardiology (2012)
Abstract 11455: Empagliflozin in Resistant Hypertension: Findings From the Empa-reg Outcome Trial
Authors: Joao Pedro Ferreira, David Fitchett, Anne Pernille Ofstad, Bettina J Kraus, Christoph Wanner, Isabella Zwiener, Sabine Lauer, Jyothis T George, Patrick Rossignol, Faiez Zannad
Journal: Circulation (2019)

Background: Patients with resistant hypertension (rHT) have increased risk of adverse outcomes and death. Type 2 diabetes (T2D) and rHT often coexist. Empagliflozin (EMPA) reduced systolic blood pr...
Response to: ‘Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’’ by Kawada
Authors: Silvia Piantoni, Laura Andreoli, Enrico Colombo, Monia Mendeni, Maria Laura Ghirardelli, Antonio Brucato, Massimo Imazio, Roberto Furloni, Franco Franceschini, Paolo Airó, Mirko Scarsi
Journal: Annals of the Rheumatic Diseases (2021)

Ethics approvalThe off-label use of colchicine was supported by the hospital administration as the emergency situation of COVID-19, which was particularly severe in Lombardy with dozens of new patients on a daily basis
AB0198 Synovial fluid analysis ? a retrospective revision
Authors: PL Nero, MM Costa, JB Pimentao, J Branco
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Synovial fluid analysis is an extension of the physical examination. In patients with crystal associated arthritis a few drops of synovial fluid often makes a definite diagnosis. <h3>Objectives</h3> The authors reviewed of synovial fluid analysis results of their Department. <h3>Methods</h3> A revision is made of all the synovial fluids seen under microscopic ordinary light, polarised light and with alizarin red stain, between the 1st. of September 1999 and the 31th of December 2000. The fluids were taken from in and outpatients of the Rheumatology Department of the Egas Moniz Hospital in Lisbon, who had a formal indication for arthrocentesis. <h3>Results</h3> A total of 114 synovial fluids were studied, 76 (66.7%) women and 38 (33.3%) men. The mean age was 60.8 ± 16.79 years. The synovial fluid was intra-articular in 76.8% and from adjacent bursal tissues in 23.2%. The mean time between arthrocentesis and microscopic analysis of the fluid was 4.72 ± 7.13 days. The fluid had mechanical properties in 32.5% of the cases; different types of crystals in 27.2%; inflammatory properties in 23.7%; 1.75% were traumatic: 0.88% were infectious; 14% were not classified. Half the patients didn't have a previous diagnosis and the synovial fluid microscopic analysis made a definite diagnosis in 40.4% of these patients: 38.6% of crystal associated arthritis and 1.85% of septic arthritis. <h3>Conclusion</h3> The synovial fluid microscopic analysis made a definite diagnosis in 40,4% in patients without a previous one, confirming it is a useful tool in clinical practice.
Abstract 16063: Effect of Fenofibric Acid on Oxidative Susceptibility of Fasting and Postprandial Lipoproteins
Authors: Ngoc-Anh Le, Peter W Wilson, W V Brown
Journal: Circulation (2012)

Fenofibric acid (FENO 135 mg/day; Trilipix®) is safe and efficacious for reduction of triglycerides (TG) with minimal effect on LDL-C. We hypothesize changes in the metabolism of TG-rich lipoprotei...
Moderate-to-Severe Acne and Mental Health Symptoms in Transmasculine Persons Who Have Received Testosterone
Authors: Hayley Braun, Qi Zhang, Darios Getahun, Michael J. Silverberg, Vin Tangpricha, Michael Goodman, Howa Yeung
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Abstract 14076: Novel Right Heart Catheterization Hemodynamic Parameters and Long Term Renal Function Among Patients With Heart Failure With Preserved Ejection Fraction
Authors: Kevin Bryan U Lo, Kene Mezue, Pradhum Ram, Abhinav Goyal, Mahek Shah, Parasuram Krishnamoorthy, Gregg Pressman, Janani Rangaswami
Journal: Circulation (2017)

Introduction: Renal dysfunction predicts poor outcomes in patients with heart failure with preserved ejection fraction (HFpEF). Right ventricular dysfunction has been implicated in worsening renal ...
Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia
Authors: Cheuk Him Man, Tsz Kan Fung, Haixia Wan, Chae Yin Cher, August Fan, Nelson Ng, Christa Ho, Thomas S. K. Wan, Toshiyuki Tanaka, Chi Wai Eric So, Yok Lam Kwong, Anskar Y. H. Leung
Journal: Blood (2015)
Citizenship Status and Prevalence of Diagnosed and Undiagnosed Hypertension and Diabetes Among Adults in the U.S., 2011–2016
Authors: Kazumi Tsuchiya, Ryan T. Demmer
Journal: Diabetes Care (2021)

In the U.S., racial and immigrant minorities are at increased risk for hypertension and diabetes mellitus (DM), with undiagnosed hypertension and DM notably higher among these groups (1,2). Noncitizen immigrants (e.g., temporary visa status, undocumented) encounter structural barriers to accessing health care as they are ineligible for health insurance, while at the same time they face multiple vulnerabilities (poverty, low wage jobs), which contribute to adverse health outcomes (3,4). Legal status, and specifically citizenship status, has been considered to be a social determinant of health (3). Citizenship status may be a critical driver of cardiovascular disease (CVD) disparities among immigrants, with noncitizens being especially vulnerable compared with either naturalized citizens or native-born citizens. However, differences between prevalence of diagnosed versus undiagnosed hypertension and DM by citizenship status remain unknown among a nationally representative sample of U.S. adults. The primary objective of the current study was to examine this issue.

We used serial cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) for the current study. NHANES uses a complex, stratified, and multistage probability sampling design …
The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD
Authors: C. Wendy Spearman, Hailemichael Desalegn, Ponsiano Ocama, Yaw Asante Awuku, Olusegun Ojo, Medhat Elsahhar, Abdulmunem A. Abdo, Dennis Amajuoyi Ndububa, Yasser Fouad, Musa Muhammed Borodo, Masolwa Ng'wanasayi, Reidwan Ally, Reda Elwakil
Journal: Journal of Hepatology (2021)